Physician profile
Zone-En Lee
NPI 1437316593
$6,224.95
in general payments reported to CMS, 2019-2025
21 companies · $1,306 in 2025
The $1,306 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2021: $73.39 · 2022: $594 · 2023: $2,035 · 2024: $2,033 · 2025: $1,306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,374.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,128.56 | 2022-2025 | |
| Celgene Corporation | $1,036.97 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $795.78 | 2021-2025 | Entyvio |
| Janssen Biotech, INC. | $647.14 | 2022-2025 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $430.29 | 2019-2024 | Xifaxan, Trulance, Plenvu |
| Genzyme Corporation | $363.20 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $295.82 | 2023-2024 | Zeposia |
| Lilly USA, LLC | $283.22 | 2023-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $279.93 | 2022-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $239.52 | 2024-2025 | Voquezna |
| Janssen Scientific Affairs, LLC | $118.67 | 2024 | Tremfya |
| Qol Medical, LLC | $110.25 | 2022-2025 | Sucraid, Sucraid |
| Gilead Sciences, INC. | $96.24 | 2023 | Vemlidy |
| Merck Sharp & Dohme LLC | $80.85 | 2022-2024 | Dificid, Zinplava |
| Pfizer INC. | $79.64 | 2023-2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $69.68 | 2021-2025 | Rebyota, Clenpiq |
| Ironwood Pharmaceuticals, INC | $50.55 | 2021-2024 | |
| Madrigal Pharmaceuticals | $34.98 | 2025 | Rezdiffra |
| Ardelyx, INC. | $33.56 | 2022-2023 | Ibsrela |
| Braintree Laboratories, INC. | $27.14 | 2023 | Sutab |
| Ipsen Biopharmaceuticals, INC | $22.96 | 2025 | Iqirvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zone-En Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.